Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Pickar, D' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 129 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Zahn, TP; Pickar, D; van Kammen, DP
      Neuroleptic effects on autonomic activity in schizophrenia: Between-group and within-subject paradigms and comparisons with controls

      SCHIZOPHRENIA BULLETIN
    2. Daly, RC; Su, TP; Schmidt, PJ; Pickar, D; Murphy, DL; Rubinow, DR
      Cerebrospinal fluid and behavioral changes after methyltestosterone administration - Preliminary findings

      ARCHIVES OF GENERAL PSYCHIATRY
    3. Pickar, D; Rubinow, K
      Pharmacogenomics of psychiatric disorders

      TRENDS IN PHARMACOLOGICAL SCIENCES
    4. Raedler, TJ; Knable, MB; Jones, DW; Lafargue, T; Urbina, RA; Egan, MF; Pickar, D; Weinberger, DR
      In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia

      NEUROPSYCHOPHARMACOLOGY
    5. Adler, CM; Elman, I; Weisenfeld, N; Kestler, L; Pickar, D; Breier, A
      Effects of acute metabolic stress on striatal dopamine release in healthy volunteers

      NEUROPSYCHOPHARMACOLOGY
    6. Hu, RJ; Malhotra, AK; Pickar, D
      Predicting response to clozapine - Status of current research

      CNS DRUGS
    7. Raedler, TJ; Knable, MB; Lafargue, T; Urbina, RA; Egan, MF; Pickar, D; Weinberger, DR
      In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine

      PSYCHIATRY RESEARCH-NEUROIMAGING
    8. Cohen, RM; Nordahl, TE; Semple, WE; Pickar, D
      The brain metabolic patterns of clozapine- and fluphenazine-treated femalepatients with schizophrenia: Evidence of a sex effect

      NEUROPSYCHOPHARMACOLOGY
    9. Breier, A; Su, TP; Malhotra, AK; Elman, I; Adler, CM; Weisenfeld, NI; Pickar, D
      Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders

      NEUROPSYCHOPHARMACOLOGY
    10. ELMAN I; GOLDSTEIN DS; EISENHOFER G; FOLIO J; MALHOTRA AK; ADLER CM; PICKAR D; BREIER A
      MECHANISM OF PERIPHERAL NORADRENERGIC STIMULATION BY CLOZAPINE

      Neuropsychopharmacology
    11. Miller, FG; Pickar, D; Rosenstein, DL
      Addressing ethical issues in the psychiatric research literature

      ARCHIVES OF GENERAL PSYCHIATRY
    12. Breier, AF; Malhotra, AK; Su, TP; Pinals, DA; Elman, I; Adler, CM; Lafargue, T; Clifton, A; Pickar, D
      Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response

      AMERICAN JOURNAL OF PSYCHIATRY
    13. Adler, CM; Malhotra, AK; Elman, I; Goldberg, T; Egan, M; Pickar, D; Breier, A
      Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    14. MALHOTRA AK; GOLDMAN D; MAZZANTI C; CLIFTON A; BREIER A; PICKAR D
      A FUNCTIONAL SEROTONIN TRANSPORTER (5-HTT) POLYMORPHISM IS ASSOCIATEDWITH PSYCHOSIS IN NEUROLEPTIC-FREE SCHIZOPHRENICS

      Molecular psychiatry
    15. PICKAR D
      THE D-2 RECEPTOR - LOVE IT AND LEAVE IT

      Molecular psychiatry
    16. MALHOTRA AK; GOLDMAN D; BUCHANAN RW; ROONEY W; CLIFTON A; KOSMIDIS MH; BREIER A; PICKAR D
      THE DOPAMINE D-3 RECEPTOR (DRD3) SER(9)GLY POLYMORPHISM AND SCHIZOPHRENIA - A HAPLOTYPE RELATIVE RISK STUDY AND ASSOCIATION WITH CLOZAPINE RESPONSE

      Molecular psychiatry
    17. PINALS DA; MALHOTRA AK; BREIER A; PICKAR D
      INFORMED CONSENT IN SCHIZOPHRENIA RESEARCH

      Psychiatric services
    18. ELMAN I; GOLDSTEIN DS; HOLMES C; PICKAR D; FOLIO J; ADLER C; BREIER A
      MECHANISM OF PERIPHERAL NORADRENERGIC STIMULATION BY CLOZAPINE

      Schizophrenia research
    19. RAEDLER TJ; KNABLE MB; LAFARGUE T; PICKAR D; WEINBERGER DR
      STRIATAL DOPAMINE D2 RECEPTOR OCCUPANCY IN PATIENTS TREATED WITH OLANZAPINE

      Schizophrenia research
    20. MALHOTRA AK; BREIER A; GOLDMAN D; PICKEN L; PICKAR D
      THE APOLIPOPROTEIN-E EPSILON-4 ALLELE IS ASSOCIATED WITH BLUNTING OF KETAMINE-INDUCED PSYCHOSIS IN SCHIZOPHRENIA - A PRELIMINARY-REPORT

      Neuropsychopharmacology
    21. COHEN RM; NORDAHL TE; SEMPLE WE; ANDREASON P; PICKAR D
      ABNORMALITIES IN THE DISTRIBUTED NETWORK OF SUSTAINED ATTENTION PREDICT NEUROLEPTIC TREATMENT RESPONSE IN SCHIZOPHRENIA

      Neuropsychopharmacology
    22. BREIER A; ADLER CM; WEISENFELD N; SU TP; ELMAN I; PICKEN L; MALHOTRA AK; PICKAR D
      EFFECTS OF NMDA ANTAGONISM ON STRIATAL DOPAMINE RELEASE IN HEALTHY-SUBJECTS - APPLICATION OF A NOVEL PET APPROACH

      Synapse
    23. MURPHY DL; KAROUM F; PICKAR D; COHEN RM; LIPPER S; MELLOW AM; TARIOT PN; SUNDERLAND T
      DIFFERENTIAL TRACE AMINE ALTERATIONS IN INDIVIDUALS RECEIVING ACETYLENIC INHIBITORS OF MAO-A (CLORGYLINE) OR MAO-B (SELEGILINE AND PARGYLINE)

      Journal of neural transmission. Supplementum
    24. MELTZER HY; CASEY DE; GARVER DL; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      MEASURING OUTCOME IN SCHIZOPHRENIA - DIFFERENCES AMONG THE ATYPICAL ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    25. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION

      The Journal of clinical psychiatry
    26. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      ADVERSE-EFFECTS OF THE ATYPICAL ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    27. MELTZER HY; CASEY DE; GARVER DL; LASAGNA S; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      ASSESSMENT OF EPS AND TARDIVE-DYSKINESIA IN CLINICAL-TRIALS

      The Journal of clinical psychiatry
    28. MELTZER HY; CASEY DE; GARVER DL; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      ASSESSING THE EFFECTS OF ATYPICAL ANTIPSYCHOTICS ON NEGATIVE SYMPTOMS

      The Journal of clinical psychiatry
    29. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      EVALUATING THE EFFECTS OF ANTIPSYCHOTICS ON COGNITION IN SCHIZOPHRENIA

      The Journal of clinical psychiatry
    30. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      ATYPICAL ANTIPSYCHOTICS FOR TREATMENT OF DEPRESSION IN SCHIZOPHRENIA AND AFFECTIVE-DISORDERS

      The Journal of clinical psychiatry
    31. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      TREATMENT OF SPECIAL POPULATIONS WITH THE ATYPICAL ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    32. MALHOTRA A; BUCHANAN R; BREIER A; PICKEN L; PICKAR D; GOLDMAN D
      ALLELIC VARIATION IN THE PROMOTER REGION OF THE DOPAMINE D-2 RECEPTORGENE INFLUENCES THE ANTIPSYCHOTIC RESPONSE TO CLOZAPINE

      American journal of medical genetics
    33. SANDERS AR; PAYLOR R; LIBBEY M; WANG J; CAO Q; ZHANG J; GOLDIN LR; PICKAR D; GERSHON ES; CRAWLEY JN; GEJMAN PV
      SUGGESTIVE EVIDENCE FOR A QUANTITATIVE TRAIT LOCUS ON CHROMOSOME-3 FOR PREPULSE INHIBITION IN THE MOUSE

      American journal of medical genetics
    34. ADLER CM; MALHOTRA AK; GOLDBERG T; PICKAR D; BREIER A
      EFFECTS OF THE NMDA ANTAGONIST, KETAMINE ON FORMAL THOUGHT-DISORDER AND ON MEMORY IN HEALTHY-VOLUNTEERS

      Naunyn-Schmiedeberg's archives of pharmacology
    35. ADLER CM; GOLDBERG TE; MALHOTRA AK; PICKAR D; BREIER A
      EFFECTS OF KETAMINE ON THOUGHT-DISORDER, WORKING-MEMORY, AND SEMANTICMEMORY IN HEALTHY-VOLUNTEERS

      Biological psychiatry
    36. ADLER CM; MALHOTRA AK; GOLDBERG T; ELMAN I; PICKAR D; BREIER A
      COMPARISON OF KETAMINE-INDUCED AND SCHIZOPHRENIC THOUGHT-DISORDER

      Biological psychiatry
    37. ELMAN I; GASTFRIEND DR; ADLER CM; MALHOTRA AK; BIR C; PICKAR D; BREIER A
      EFFECTS OF ACUTE METABOLIC STRESS ON PITUITARY-ADRENAL AXIS ACTIVATION IN PATIENTS WITH SCHIZOPHRENIA

      Biological psychiatry
    38. SU TP; PICKAR D; BREIER A
      DEXTROAMPHETAMINE-INDUCED NEUROCHEMICAL EFFECTS IN CHRONIC-SCHIZOPHRENICS AND HEALTHY-VOLUNTEERS

      Biological psychiatry
    39. ELMAN I; ADLER CM; MALHOTRA AK; BIR C; PICKAR D; BREIER A
      EFFECT OF ACUTE METABOLIC STRESS ON PITUITARY-ADRENAL AXIS ACTIVATIONIN PATIENTS WITH SCHIZOPHRENIA

      The American journal of psychiatry
    40. BREIER A; KESTLER L; ADLER C; ELMAN I; WIESENFELD N; MALHOTRA A; PICKAR D
      DOPAMINE D-2 RECEPTOR DENSITY AND PERSONAL DETACHMENT IN HEALTHY-SUBJECTS

      The American journal of psychiatry
    41. Goldberg, TE; Aloia, MS; Gourovitch, ML; Missar, D; Pickar, D; Weinberger, DR
      Cognitive substrates of thought disorder, I: The semantic system

      AMERICAN JOURNAL OF PSYCHIATRY
    42. Aloia, MS; Gourovitch, ML; Missar, D; Pickar, D; Weinberger, DR; Goldberg, TE
      Cognitive substrates of thought disorder, II: Specifying a candidate cognitive mechanism

      AMERICAN JOURNAL OF PSYCHIATRY
    43. RAPAPORT MH; MCALLISTER CG; PICKAR D; TAMARKIN L; KIRCH DG; PAUL SM
      CSF IL-1 AND IL-2 IN MEDICATED SCHIZOPHRENIC-PATIENTS AND NORMAL VOLUNTEERS

      Schizophrenia research
    44. PAYLOR R; PICKAR D; CRAWLEY JN
      CHARACTERIZATION OF INBRED MOUSE STRAIN DIFFERENCES IN STARTLE AND THE PREPULSE INHIBITION MODEL OF SCHIZOPHRENIA

      Schizophrenia research
    45. BUCHANAN RW; MALHOTRA A; KIRKPATRICK B; GOLDMAN D; BREIER A; PICKAR D
      LACK OF ASSOCIATION BETWEEN 5HT2A, 5HT2C, AND D4 RECEPTOR GENE POLYMORPHISMS AND THE DEFICIT SYNDROME OF SCHIZOPHRENIA

      Schizophrenia research
    46. BREIER A; SU TP; SAUNDERS R; CARSON RE; KOLACHANA BS; WEISENFELD N; MALHOTRA AK; ELMAN I; ECKELMAN WC; PICKAR D
      ASSESSMENT OF SYNAPTIC DOPAMINE CONCENTRATIONS IN SCHIZOPHRENIA WITH PET

      Schizophrenia research
    47. ELMAN I; GOLDSTEIN DS; HOLMES C; ADLER C; PICKAR D; BREIER A
      THE EFFECTS OF CLOZAPINE ON PLASMA NOREPINEPHRINE KINETICS IN SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    48. MALHOTRA AK; BREIER A; BUCHANAN R; GOLDMAN D; PICKAR D
      THE NMDA RECEPTOR AND SCHIZOPHRENIA - FROM PHENOTYPE TO GENOTYPE

      Schizophrenia research
    49. PICKAR D; GOLDMAN D; BUCHANAN R; BREIER A; MALHOTRA AK
      PREDICTING CLOZAPINE RESPONSE - SYSTEMATIC EVALUATION OF ALLELIC VARIATION IN CANDIDATE GENES

      Schizophrenia research
    50. MALHOTRA AK; PINALS DA; ADLER CM; ELMAN I; CLIFTON A; PICKAR D; BREIER A
      KETAMINE-INDUCED EXACERBATION OF PSYCHOTIC SYMPTOMS AND COGNITIVE IMPAIRMENT IN NEUROLEPTIC-FREE SCHIZOPHRENICS

      Neuropsychopharmacology
    51. CARSON RE; BREIER A; DEBARTOLOMEIS A; SAUNDERS RC; SU TP; SCHMALL B; DER MG; PICKAR D; ECKELMAN WC
      QUANTIFICATION OF AMPHETAMINE-INDUCED CHANGES IN [C-11] RACLOPRIDE BINDING WITH CONTINUOUS-INFUSION

      Journal of cerebral blood flow and metabolism
    52. DEBARTOLOMEIS A; KOPRIVICA V; PICKAR D; CRAWLEY JN; ABBOTT LC
      OPIOIDERGIC AND DOPAMINERGIC GENE-EXPRESSION IN THE CAUDATE-PUTAMEN AND ACCUMBENS OF THE MUTANT MOUSE, TOTTERING (TG TG)/

      Molecular brain research
    53. MALHOTRA AK; GOLDMAN D; MAZZANTI C; CLIFTON A; BREIER A; PICKAR D
      A FUNCTIONAL SEROTONIN TRANSPORTER POLYMORPHISM IS ASSOCIATED WITH PSYCHOSIS IN NEUROLEPTIC-FREE SCHIZOPHRENICS

      American journal of medical genetics
    54. PICKAR D; MALHOTRA AK; ROONEY W; BREIER A; GOLDMAN D
      APOLIPOPROTEIN-E EPSILON-4 AND CLINICAL PHENOTYPE IN SCHIZOPHRENIA

      Lancet
    55. MALHOTRA AK; GOLDMAN D; BUCHANAN R; PICKAR D; BREIER A
      THE ANTIPSYCHOTIC EFFICACY OF CLOZAPINE AND NMDA RECEPTOR FUNCTION - EVIDENCE FROM CLINICAL AND MOLECULAR STUDIES

      Psychopharmacology bulletin
    56. BREIER A; SU TP; SAUNDERS R; CARSON RE; KOLACHANA BS; DEBARTOLOMEIS A; WEINBERGER DR; WEISENFELD N; MALHOTRA AK; ECKELMAN WC; PICKAR D
      SCHIZOPHRENIA IS ASSOCIATED WITH ELEVATED AMPHETAMINE-INDUCED SYNAPTIC DOPAMINE CONCENTRATIONS - EVIDENCE FROM A NOVEL POSITRON EMISSION TOMOGRAPHY METHOD

      Proceedings of the National Academy of Sciences of the United Statesof America
    57. MALHOTRA AK; ADLER CM; KENNISON SD; ELMAN I; PICKAR D; BREIER A
      CLOZAPINE BLUNTS N-METHYL-D-ASPARTATE ANTAGONIST-INDUCED PSYCHOSIS - A STUDY WITH KETAMINE

      Biological psychiatry
    58. BERTOLINO A; ADLER C; CALLICOTT J; SANTHA A; PODELL D; MALHOTRA A; MATTAY V; PICKAR D; FRANK J; BREIER A; WEINBERGER DR
      EFFECTS OF KETAMINE ON WORKING-MEMORY CIRCUITRY AS STUDIED BY WHOLE-BRAIN FMRI

      Biological psychiatry
    59. ADLER CM; MALHOTRA AK; GOLDBERG T; ELMAN I; WEINBERGER D; PICKAR D; BREIER A
      EFFECTS OF THE NMDA ANTAGONIST, KETAMINE ON THOUGHT-DISORDER AND COGNITION

      Biological psychiatry
    60. MALHOTRA AK; ADLER CM; CLIFTON A; ELMAN I; PICKAR D; BREIER A
      CLOZAPINE BLUNTS NMDA ANTAGONIST-INDUCED PSYCHOSIS - A STUDY WITH KETAMINE

      Biological psychiatry
    61. ELMAN I; GOLDSTEIN DS; HOLMES C; PICKAR D; ADLER C; BREIER A
      CLOZAPINE-INDUCED ELEVATION IN NOREPINEPHRINE - RELATION TO ARTERIAL PLASMA SPILLOVER

      Biological psychiatry
    62. LITMAN RE; TORREY EF; HOMMER DW; RADANT AR; PICKAR D; WEINBERGER DR
      A QUANTITATIVE-ANALYSIS OF SMOOTH-PURSUIT EYE TRACKING IN MONOZYGOTICTWINS DISCORDANT FOR SCHIZOPHRENIA

      Archives of general psychiatry
    63. COHEN RM; NORDAHL TE; SEMPLE WE; ANDREASON P; LITMAN RE; PICKAR D
      THE BRAIN METABOLIC PATTERNS OF CLOZAPINE-TREATED AND FLUPHENAZINE-TREATED PATIENTS WITH SCHIZOPHRENIA DURING A CONTINUOUS PERFORMANCE TASK

      Archives of general psychiatry
    64. SU TP; MALHOTRA AK; HADD K; BREIER A; PICKAR D
      D-2 DOPAMINE-RECEPTOR OCCUPANCY - A CROSSOVER COMPARISON OF RISPERIDONE WITH CLOZAPINE THERAPY IN SCHIZOPHRENIC-PATIENTS

      Archives of general psychiatry
    65. BREIER A; MALHOTRA AK; PINALS DA; WEISENFELD NI; PICKAR D
      ASSOCIATION OF KETAMINE-INDUCED PSYCHOSIS WITH FOCAL ACTIVATION OF THE PREFRONTAL CORTEX IN HEALTHY-VOLUNTEERS

      The American journal of psychiatry
    66. JACOBSEN LK; FRAZIER JA; MALHOTRA AK; KAROUM F; MCKENNA K; GORDON CT; HAMBURGER SD; LENANE MC; PICKAR D; POTTER WZ; RAPOPORT JL
      CEREBROSPINAL-FLUID MONOAMINE METABOLITES IN CHILDHOOD-ONSET SCHIZOPHRENIA

      The American journal of psychiatry
    67. MALHOTRA AK; GOLDMAN D; OZAKI N; ROONEY W; CLIFTON A; BUCHANAN RW; BREIER A; PICKAR D
      CLOZAPINE RESPONSE AND THE 5HT(2C)CYS(23)SER POLYMORPHISM

      NeuroReport
    68. PINALS DA; MALHOTRA AK; MISSAR CD; PICKAR D; BREIER A
      LACK OF GENDER DIFFERENCES IN NEUROLEPTIC RESPONSE IN PATIENTS WITH SCHIZOPHRENIA

      Schizophrenia research
    69. MALHOTRA AK; PINALS DA; WEINGARTNER H; SIROCCO K; MISSAR CD; PICKAR D; BREIER A
      NMDA RECEPTOR FUNCTION AND HUMAN COGNITION - THE EFFECTS OF KETAMINE IN HEALTHY-VOLUNTEERS

      Neuropsychopharmacology
    70. PICKAR D
      NEW STRATEGIES FOR TREATING PSYCHOSIS - INTRODUCTION

      The Journal of clinical psychiatry
    71. MALHOTRA AK; GOLDMAN D; BUCHANAN R; BREIER A; PICKAR D
      5HT(2A) RECEPTOR T102C POLYMORPHISM AND SCHIZOPHRENIA

      Lancet
    72. PICKAR D
      CLOZAPINE FOR TREATMENT OF SCHIZOPHRENIA - REPLY

      JAMA, the journal of the American Medical Association
    73. MALHOTRA AK; PICKAR D
      BIOLOGIC PREDICTORS OF CLOZAPINE RESPONSE IN SCHIZOPHRENIA

      Psychiatric annals
    74. LITMAN RE; SU TP; POTTER WZ; HONG WW; PICKAR D
      IDAZOXAN AND RESPONSE TO TYPICAL NEUROLEPTICS IN TREATMENT-RESISTANT SCHIZOPHRENIA - COMPARISON WITH THE ATYPICAL NEUROLEPTIC, CLOZAPINE

      British Journal of Psychiatry
    75. BREIER A; SU TP; WEISENFELD N; ELMAN I; ADLER C; MALHOTRA AK; PICKAR D
      ASSESSMENT OF STRIATAL DOPAMINE FUNCTION IN SCHIZOPHRENIA

      Biological psychiatry
    76. SU TP; BREIER A; COPPOLA R; HADD K; ELMAN I; ADLER C; MALHOTRA AK; WATSKY E; GOREY J; WEINBERGER D; PICKAR D
      D2 RECEPTOR OCCUPANCY IN RISPERIDONE AND CLOZAPINE-TREATED SCHIZOPHRENICS

      Biological psychiatry
    77. MALHOTRA AK; PINALS DA; WEISENFELD N; PICKAR D; BREIER A
      NMDA RECEPTOR FUNCTION AND SCHIZOPHRENIA - STUDIES WITH KETAMINE

      Biological psychiatry
    78. ELMAN I; WIESENFELD N; SU TP; MALHOTRA AK; PICKAR D; BREIER A
      THE EFFECTS OF METABOLIC AND COGNITIVE STRESS ON CEREBRAL BLOOD-FLOW

      Biological psychiatry
    79. BERTOLINO A; CALLICOTT JH; ELMAN I; DUYN JH; TEDESCHI G; FRANK JA; PICKAR D; WEINBERGER DR
      PROTON MAGNETIC-RESONANCE SPECTROSCOPIC IMAGING IN DRUG-FREE PATIENTSWITH SCHIZOPHRENIA - REGIONAL NEURONAL DAMAGE

      Biological psychiatry
    80. ELMAN I; BIR C; PICKAR D; BREIER A
      NEUROENDOCRINOLOGICAL IMPACTS OF GLUCOPRIVIC STRESS

      Biological psychiatry
    81. MALHOTRA AK; GOLDMAN D; OZAKI N; BREIER A; BUCHANAN R; PICKAR D
      LACK OF ASSOCIATION BETWEEN POLYMORPHISMS IN THE 5-HT2A RECEPTOR GENEAND THE ANTIPSYCHOTIC RESPONSE TO CLOZAPINE

      The American journal of psychiatry
    82. DANIEL DG; GOLDBERG TE; WEINBERGER DR; KLEINMAN JE; PICKAR D; LUBICK LJ; WILLIAMS TS
      DIFFERENT SIDE-EFFECT PROFILES OF RISPERIDONE AND CLOZAPINE IN 20 OUTPATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER - A PILOT-STUDY

      The American journal of psychiatry
    83. PICKAR D; SU TP; WEINBERGER DR; COPPOLA R; MALHOTRA AK; KNABLE MB; LEE KS; GOREY J; BARTKO JJ; BREIER A; HSIAO J
      INDIVIDUAL VARIATION IN D-2 DOPAMINE-RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS

      The American journal of psychiatry
    84. GEJMAN PV; GELERNTER J; CRAVCHIK A; GERSHON ES; PICKAR D
      TESTING PATHOPHYSIOLOGIC HYPOTHESES OF PSYCHIATRIC-ILLNESS BY MOLECULAR-GENETIC APPROACHES

      Schizophrenia research
    85. BREIER A; CARSON R; ECKELMAN W; DEBARTOLOMEIS A; SAUNDERS RC; WEINBERGER D; SU TP; PICKAR D
      IN-VIVO ESTIMATES OF SYNAPTIC DOPAMINE CONCENTRATIONS WITH C-11 RACLOPRIDE PET - A DIRECT TEST OF THE DOPAMINE HYPOTHESIS/

      Schizophrenia research
    86. BREIER A; MALHOTRA A; PINALS D; CHUNG IW; HIDARY J; SU TP; HSIAO J; PICKAR D
      NEUROANATOMICAL LOCALIZATION OF NMDA RECEPTOR-MEDIATED PSYCHOSIS IN HEALTHY CONTROLS AND SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    87. HSIAO JK; CHUNG IW; COHEN R; PICKAR D
      REGIONALLY SPECIFIC CHANGES IN BRAIN GLUCOSE-METABOLISM ASSOCIATION WITH RESPONSE TO CLOZAPINE TREATMENT

      Schizophrenia research
    88. PICKAR D; SU TP; COPPOLA R; LEE CS; HSIAO JK; BREIER A; WEINBERGER DR
      DA OCCUPANCY AND DOPAMINE RELEASE DETERMINED BY I-123 IBZM SPECT FOLLOWING CLOZAPINE DOSE REDUCTION

      Schizophrenia research
    89. DANIEL DG; GOLDBERG TE; LUBICK LJ; WEINBERGER DR; KLEINMAN JE; PICKAR D; WILLIAMS TS
      SELF-REPORTED COGNITIVE IMPAIRMENT PREDICTS PATIENT PREFERENCE BETWEEN RISPERIDONE AND CLOZAPINE

      Schizophrenia research
    90. MALHOTRA AK; WEINGARTNER H; SIROCCO K; PINALS D; MISSAR CD; PICKAR D; BREJER A
      THE COGNITIVE EFFECTS OF KETAMINE, AN NMDA ANTAGONIST, IN NORMAL CONTROLS AND DRUG-FREE SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    91. PICKAR D
      MECHANISM OF ACTION OF CLOZAPINE - IMPLICATIONS FOR A NEW-GENERATION OF ANTIPSYCHOTICS

      Schizophrenia research
    92. PINALS DA; MALHOTRA AK; MISSAR CD; BREIER A; PICKAR D
      THE ROLE OF GENDER IN THE PHARMACOTHERAPY OF SCHIZOPHRENIA

      Schizophrenia research
    93. SU TP; TUSKAN J; TSAO L; PICKAR D
      AGGRESSION DURING DRUG-FREE AND ANTIPSYCHOTIC TREATMENT IN INPATIENTSWITH CHRONIC-SCHIZOPHRENIA, USING THE OVERT AGGRESSION SCALE

      Schizophrenia research
    94. PICKAR D
      PHARMACOTHERAPY OF SCHIZOPHRENIA

      Lancet
    95. PICKAR D
      PROSPECTS FOR PHARMACOTHERAPY OF SCHIZOPHRENIA

      Lancet
    96. PICKAR D; HSIAO JK
      CLOZAPINE TREATMENT OF SCHIZOPHRENIA

      JAMA, the journal of the American Medical Association
    97. ZHAN TP; PICKAR D
      EFFECTS OF A LOW-ANTICHOLINERGIC NEUROLEPTIC ON AUTONOMIC ACTIVITY INSCHIZOPHRENIA

      Psychophysiology
    98. ZARATE CA; DANIEL DG; KINON BJ; LITMAN RE; NABER D; PICKAR D; SATO M
      INTERNATIONAL PSYCHOPHARMACOLOGY ALGORITHM PROJECT REPORT .A. ALGORITHMS FOR THE TREATMENT OF SCHIZOPHRENIA

      Psychopharmacology bulletin
    99. CHUNG IW; KIM YS; AHN JS; LEE HS; CHEN G; MANJI HK; POTTER WZ; PICKAR D
      PHARMACOLOGICAL PROFILE OF NATURAL-PRODUCTS USED TO TREAT PSYCHOTIC ILLNESSES

      Psychopharmacology bulletin
    100. SCHREIBER JL; BREIER A; PICKAR D
      EXPRESSED EMOTION - TRAIT OR STATE

      British Journal of Psychiatry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 19:03:38